Novo Nordisk Weaves a Safety Net: Hemophilia Drug Advances as GLP-1 Revenue Faces Halving in 2027
Novo Nordisk is trying to rebuild its story on two fronts at once. The Danish drugmaker’s stock has…
Novo Nordisk’s CagriSema Advances as Data Breach Tests Investor Confidence
Novo Nordisk finds itself navigating two starkly different narratives this week. On one hand, the Danish pharma giant…
Novo Nordisk’s Combination Strategy Takes Center Stage as Pipeline Advances, Shares Stay Muted
Novo Nordisk shares drop 4.57%, 47% off high, yet pipeline progress includes Veru collaboration on Wegovy combo, ADA…
High-Dose Wegovy Fat-Loss Data and Hemophilia Drug Near Approva
Novo Nordisk reveals STEP-UP trial data for high-dose Wegovy showing 21% weight loss with muscle preservation, alongside hemophilia…
European Lithium’s Rare Earth Blitz Advances in Greenland as Merger Math and Austrian Woes Temper th
European Lithium stock surges 205% YTD, but faces headwinds: Morgan Stanley exits, A$24M shortfall for Critical Metals merger,…
Novo Nordisk Juggles Pipeline Advances and Generic Threat as Share Buyback Hits $3.44 Billion
Novo Nordisk launches Phase 3 knee OA trial, gains FDA fast-track for heart drug, as first Ozempic generic…
Novo Nordisk’s Sickle Cell Drug Delivers as Buyback Program Advances
Novo Nordisk’s oral sickle cell drug etavopivat met Phase 3 goals, cutting painful crises by 27%. The success…
European Lithium’s Valuation Gap Narrows as Greenland Project Advances
European Lithium’s 12% surge follows Greenland project approval, revealing a valuation gap where its cash and Critical Metals…
Novo Nordisk Advances Share Buyback Amid Market Pressures
Danish pharmaceutical giant Novo Nordisk is proceeding with its multi-billion kroner share repurchase initiative, a move that underscores…